Leronlimab (PRO 140) is a humanized IgG4, C–C chemokine receptor type 5 (CCR5), monoclonal antibody receptor antagonist originally studied in the treatment of HIV for which it has been shown to be effective and well tolerated [[31], [32], [33], [34], [35]] and currently being investigated for the treatment of COVID-19. Here, CCR5 is linked to COVID-19.